The FDA announced in late April the approval of once-daily 800/200 mg lopinavir/ritonavir (Kaletra) tablets and oral solution for use by previously treated HIV positive adults without extensive lopinavir resistance. Once-daily administration is not recommended for children or for adults with three or more lopinavir resistance-associated mutations.
Twice-daily lopinavir/ritonavir was initially approved for treatment-experienced patients in September 2000; once-daily dosing was later added for treatment-naive individuals. The new regimen is supported by data from Study 802, a Phase III randomized clinical trial showing similar efficacy and tolerability with once-daily and twice-daily dosing.
Liz Highleyman (email@example.com) is a freelance medical writer based in San Francisco.
This article was provided by San Francisco AIDS Foundation. It is a part of the publication Bulletin of Experimental Treatments for AIDS. Visit San Francisco AIDS Foundation's Web site to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)